ArticleThe journal of allergy and clinical immunology. Global2026
AI-based prediction of aspirin-exacerbated respiratory disease using nasal epithelial mRNA expression profiles.
Article in The journal of allergy and clinical immunology. Global, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Aspirin-exacerbated respiratory disease (AERD) is a distinct asthma endotype marked by asthma, nasal polyposis, and respiratory reactions to COX-1 inhibitors. Early and accurate identification of AERD remains clinically challenging. Objective: We sought to develop and externally validate an artificial intelligence (AI)-based diagnostic model that uses nasal epithelial mRNA expression profiles to accurately identify AERD. Methods: mRNA gene expression profiles were obtained from nasal epithelial brushing in 71 subjects with AERD and 57 without AERD. AI models were trained to predict an AERD diagnosis in a Results: The clinical data analysis revealed noteworthy findings of AERD: 29% reported cutaneous manifestations during nonsteroidal anti-inflammatory drug reactions, 50% experienced symptoms related to alcohol consumption, and 59% required 2 or more sinus surgeries. AERD was predicted with an accuracy of 93% in the training cohort and 83% in the independent validation cohort. The top AERD-predicting genes included Conclusions: Nasal transcriptomics can predict AERD diagnosis accurately and may improve disease understanding, enabling earlier and more precise endotype-based diagnosis and management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.